Concepedia
Statistics
Publications
38
Citations
3.5K
H-Index
25
Active since
1989
Affiliations
Astex Pharmaceuticals(Current)
University of Chicago
Northwestern University
The University of Texas MD Anderson Cancer Center
Cornell University
Harold Keer is an author at Astex Pharmaceuticals specializing in medicine, oncology, and pharmacology.
Publications per year
1989–2025
Mutation of the Androgen-Receptor Gene in Metastatic Androgen-Independent Prostate Cancer
Mary‐Ellen Taplin, Glenn J. Bubley, Todd D. Shuster et al. · New England Journal of Medicine · 1995 · 1.3K citations · Full text
Medicine, Genetics, Oncology +17
Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer
Manish A. Shah, Zev A. Wainberg, Daniel V.T. Catenacci et al. · PLoS ONE · 2013 · 206 citations · Full text
Medicine, Oncology, Pharmacology +17
A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2
Joseph P. Eder, Geoffrey I. Shapiro, Leonard J. Appleman et al. · Clinical Cancer Research · 2010 · 193 citations · Full text
Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer
Tony Reid, Frank H. Valone, William LiPera et al. · Lung Cancer · 2004 · 162 citations
Medicine, Medicinal Chemistry, Oncology +16
An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations
Nicholas Pulliam, Fang Fang, Ali Özeş et al. · Clinical Cancer Research · 2018 · 128 citations · Full text
1–5 of 38